We claim:

(1) A process to obtain highly pure 4-(cyclopropylcarbonyl)-α,α-dimethylphenylacetic acid of Formula I comprising the steps of:



Formula I

dissolving a mixture of para and meta regioisomers of Formula VIII in a suitable crystallization solvent such as a hydrocarbon or an ether to obtain a solution,



Mixture of para and meta regioisomers of Formula VIII

optionally seeding the said solution with a small quantity of pure para isomer of Formula I,

cooling the said solution to obtain selectively crystallized isomer of Formula I such that the amount of meta isomer of Formula II in the said crystallized isomer of Formula I is below 0.5% by weight.



Formula II

(2) The process according to claim 1 wherein the said crystallization solvent is selected from the group consisting of hexane, heptane, cyclohexane, diethyl ether, diisopropyl ether and mixtures thereof.

(3) The process according to claim 1 wherein the said crystallization solvent is cyclohexane.

(4) A process to produce para-isomerically pure terfenadine carboxylate of Formula III comprising the steps of:



Formula III

dissolving a mixture of para and meta regioisomers of Formula VIII in a suitable crystallization solvent such as a hydrocarbon or an ether to obtain a solution,



Mixture of para and meta regioisomers of Formula VIII

optionally seeding the said solution with a small quantity of pure para isomer of Formula I,

cooling the said solution to obtain selectively crystallized isomer of Formula I



Formula I

such that the amount of meta isomer of Formula II in the said crystallized isomer of Formula I is below 0.5% by weight,

reacting the said crystallized isomer of Formula I with a piperidine compound of Formula IV to form the piperidine derivative compound of Formula XI,



Formula IV



Formula XI

reacting the keto group of the compound of Formula XI to convert it to a hydroxyl group by reduction reaction to obtain a terfenadine carboxylate of Formula III that contains less than 0.1% of meta regioisomer.

(5) The process according to claim 4 wherein the said crystallization solvent is selected from the group consisting of hexane, heptane, cyclohexane, diethyl ether, diisopropyl ether and mixtures thereof.

(6) The process according to claim 4 wherein the said crystallization solvent is cyclohexane.